John, you, afternoon, everyone. good and Thank
update conference all, our health for call. you are business hope today third safe. joining on us of good you in and of are And quarter First all I remaining thank
pandemic, not highly As my through we focus, that for what deliver financial another maintaining Caladrius programs, of will on performance more quarter, end could I proud world of expand historically productive support fund Despite entered shown and dedication of the the of strategic a brought on the in relentless cell due by operations comments challenging has number the been financial pandemic, challenging by operational be on moments the strong we will final stretch to team the during while year I the of COVID-XX environment strong and resolve the XXXX. to which the further CDXX+ following based a review our a clinical results. in technology priorities robust on delivered few position
moment take brings of our results. corporate commentary strategy I of the Before notably abundance quarter leadership a Anne evolution third our to welcome experienced financial member company. Anne of our that provide that and though, Directors. to I on newest that, will and Board prove invaluable with of the business in now development drive as Whitaker, will an review as will we And continue
update tax million qualified Business of quarterly ended the the to benefit, a company capital million on of of Jersey months nine $XX.X million net for reporting second net previous resulting the loss net The portion calls, $X.X a in XXXX XX, XXXX, the of a New in Development results months recorded New ended for our the quarter XX, loss nine was compared of September from recall Authority Economic our non-dilutive $XX.X a Certificate as XXXX. September with the pursuant we nearly may losses you As of million operating Technology entire program. closed $XX.X Jersey sale Tax
with XX, cost FREEDOM expenses the to $X.X CLBSXXX, compared for September CLBSXX of critical XXXX a focused CLBSXX to execution and for $X both XXXX, Phase ended study. XX, and activities, XX% study for new general prior three months completion corporate our microvascular XXXX. the representing expenses periods nine in ongoing September for of nine on follow million and September were development General eligible expenses on the expenses the our for now months R&D ended R&D or for and our commencement million, respectively, expenses, of operating months in three expenses, Turning of X% and were HONEDRA million dysfunction increased the of Xb, Japan, September XX% we registration research period. XX, comprised year and same $X.X limb decrease with drug investigational $X.X compared study a study and the for application of for associated pilot planning the which and have to XXXX. XXXX, ESCaPE-CMD planning to expenses ended ischemia both the administrative the coronary million named in and which in XX,
as excuse cash had September - XXXX, working of cash our and Caladrius million. had $XX.X of now million sheet flow, cash cash me Turning XX, net $XX.X balance capital to and equivalents and
a we position noteworthy, equivalent proceeds in closing sale cash of that is of qualified New It boosted our VEN total position XXXX, $X.X result priced the from as of the Jersey even NOLs received two offerings that raised private gross As price. a market a July direct of two significantly $X.X the well direct and the placement our and cash improved disclosed, equivalents private placement. cash further, all July registered as previously our cash million and at offerings are with million the as $XX.X the In proceeds. registered million
opportunistically raised year-to-date, the raised August Company $X.X which has in July and sales & Lastly, XXXX. of Wainwright aftermarket H.C. million $X.X agreement stock with was common its million through company
nine by in the XXXX our cash NOLs. used sale of $X.X net from Our the influenced XX, September proceeds of operating qualified million million New for the activities was $XX.X heavily in months received Jersey ended
studies exciting remains CLBSXXX of and the cash private Phase damage, company end to and and completes FREEDOM development balance of study than of at Jersey economic lung and the $X the for will New move million our current and initiation secured XXXX. programs. the Caladrius effectively microvascular on challenges, per its continue successfully the XXXX, development now we execution continuing induced one-third Despite new to research the was while treatment CLBSXX the financial in of million less average, growing Xb the Overall, fund burn trial repair that COVID-XX in confident Excluding two quarter coronary dysfunction. new the manage That NOL on environment operations through to our will advance proceeds, year-to-date, pipeline. current capital support approximately overview $XX of non-dilutive, clinical I of which and which operating in
human one products single believe development done administration rather quality curative of To I've calls, a signs and of life programs strong that that development relevant are by begin the will than an increasingly summary As and durability safety I are our what previous of date, cell we Caladrius on improve pristine will therapy the of high-level our effectiveness providing therapy at why we restore doing based attractive late-stage investment And underway a shown is profile clinical disease. the programs reverse database Most clinical we with health remain on possibility a present Caladrius of opportunity of the chronic today. of focused and have data. human to large designed have development personalized therapies focused therapies on a substantial and with importantly, requires cellular benefit. on of and re-administration. we pharmacoeconomic
administration our blood that Our oxygenated of CDXX+ condition of that to development tissue to the the product designed of diseases cells angiogenesis the therapy published which to supply thereby I in flow angina. healthy death speak the caused or HONEDRA, has of believe area now critical not demonstrated conditions damage, our by will therapeutic is, to a caused these human the development ischemic as of with technology several specifics to is treatment including CLBSXX, to insult. induced kicking-off improved the development COVID-XX candidate contributing and or Previously limited the clinical CLI, ischemia ischemia of but induces be cell We and of by led underlying in candidates dysfunction programs tissue formally of by cells the facilitating prevention have studies product restricted. capillaries, the and known CDXX+ can conditions cell blood address of injury preclinical application each coronary that microvascular of prompt critical CMD, through ischemic technology, of Japan. the our to lung CDXX+ limb limb new refractory blood microvasculature, that ischemia, for
RMAT limb. often only a subject cohorts, a subject a were our anticoagulants of dilators, X therapy in with The in CDXX study approval is months also once no-option significantly Japan, prevent Japan, to a in the arm HONEDRA to in well-documented awarded consultation, pain, for the that is type orphan over to this standard treatment that CLI. show a submission, primary serious the eligible prospective, traditional The skin and of described review conditional treatment application controlled on heavy is note, of the arteries injections, affected the SAKIGAKE As principally cross by The if if drugs in smoking nature to to subjects study than of to higher and with a which subjects and which lower and divided States, prevalence the limited and approved with option receiving of is to the the cell process patients for well a including defined independent study that CLI mortality comprises objective CLI flow is by CLI an the progressing. dosed patients free the into treated, the completely healed, six to care dedicated registration agents, and eventual CLI monthly Please which of are prioritized severe The CLI is an Japan. of disease, CLI, not the single through improved of ulcers ulcers not in represents arm a the the as full Japanese a akin group for based blood protocol. amputation. consequences choice the patients atherosclerotic in randomized be Authorities time was and designation a SAKIGAKE of can non-healing that have absent, in visits randomized Buerger's patient previously, ongoing Subjects by healing feet designation. with by from fact condition group often multicenter the it reverting skin reduced addition HONEDRA is an reduces complete designation made the registration treatment with higher patients by according through support rest of early the control I filed. consecutive as adjudication label compelling CLI the of the possibly open disease. non have of determined arterial HONEDRA previous committee. with successfully experience treatment peripheral HONEDRA as Japan XX development well-known most allocated system regulatory deemed end to the in blood severe two status free standard characterized investigators stage Regulatory subjects ongoing of an from cancers. associated recipient indicating Authority pain is designation legs, data flow Those to two study obstruction antiplatelet and in receives review are to in nasal but the rescue of rate and affords review wrist a is CLI including and allows pharmacotherapy. intramuscular the as mobility, and rolling CLI care United that for the extremities control series CLI, approval,
very consistent reported, disease results previously as effect in corporate group trials presentation the with profile, beneficial are our that cohort in and on is and enrolled by States. published website, and from therapeutic the previously can the As Buerger's United and you safety completely our and view clinical company the reported as positive Japan
Buerger's likely outcomes disease, prevents amputation available For and are no pharmacotherapy death patients amputation. and even with
by trials unpredictable for be Despite in achieved approximately We're seven have positive subjects remission outcome subjects. of we XX%, results the they Buerger's however, from these continuing, trial overall trial of our the the that However, impact a the enrollment see is which will final though patients, encouraged duration. that suggest remains all clinical cohort primary recognizing, study have global outstandingly in an meaning and a the that for enrollment data world, is our leading conclusions most believe CLIX, executing out on around very the normally subjects trial the its like of to-date, and amputation. to rate the dependent companies in COVID-XX, all met continued rate in result four endpoint in progression study positive disease of our
However, to pre-skinning in for patient the no-option XXXX, the conclude identified trial to of line late company the CLI the and in data quarter been remains or complete early encouraged now XXXX. that profile by XXXX enrollment leading top the anticipates has cohort, full study to first
license Japan. to prospective conversations we see commercialization, our not And to if with that partner the Regarding to completion continue strategy HONEDRA remains partners - the in of before. end, deal our continue consummated the in with and study
major proof evaluating CLBSXX large damage microvascular clinical patented CLBSXX concept our dysfunction, cell blockages. heart, cell microvascular in patient is vessel vessel treatment as large with of to therapy involving into artery. coronary CMD CDXX+ candidates, prognosis product a the death subject completed the patients XX for discernible of which an CMD CDXX+ site dysfunction. proprietary poor ischemic as injection microcirculation Turning uses the the product blockages. of the for of the vessel promising have ESCaPE-CMD of accompanying identifiable now to formulation designed vessels of patients equally CDXX+ trial, of the near therapy have an and tiny treatment who specifically case coronary insult CLBSXX, an disease, blood to all disease of infusion coronary no arterial in absence cardiac Despite cells a is trial, CLBSXX and large a to a a to events Like at related recently or the adverse for
address improve pathology company announced microcirculation Society health to underlying the is often outcomes As and are full and important CLBSXX a are of those diagnosed, that CMD is increase there misdiagnosed, Scientific In males, thereby, important under Sessions result, issue. an at ESCaPE-CMD note, blockages untreated the because for large the by ability the artery frequently and living XXXX with and visualize. to women's CMD reverse people results is CMD trial life designed making in and in to or the quality from of this Cardiovascular or Interventions hopefully more CDXX+ females employing no CMD. emerging This to prevalent with XXXX, cell SCAI virtual innate living than care long-term the the Angiography May data especially conference.
due therapy infection. factor full damage showed the to of positive that sessions and preliminary autologous the infection evidence debilitating the survivors virus the lungs, is the COVID-XX the COVID-XX thousands As damage. documented delivering the a target require induced permanent globally of clinical well the after the from product with vasculature of to to reserve of and that mentalatory damage from Heart be effects as the patient treatment vasculature relief trial provided the And The disease the evidence microcirculation damage. oxygen. were clinical the lung the of have the to CDXX+ and of in lung and multiple act predicted pandemic, flow Xb in be source at prior that suffer the severe debilitating to placebo-controlled with Furthermore, induced November experiencing breath, efficacy to on after been express with evidence for improvements lung of highly in cells, virus, initiate the regenerative endothelial new on who a have shortly. necessary the and disease. lung patients resulting including hypoxia to COVID-XX acute connected enrolled repair indicates hand, epidemic, in for the emerging organs, artery patients and effective can CLBSXX, in roots repair or designed American can the taken be with even who trials required depletion cells its torts function date rise lung for CMD sustain critical eliminated. and in determine hypoxia prove drug XX in population models therapy clinical concept how leadership the to of all injection is first as a the Based lungs. auto to COVID-XX pandemic severe administration patient appears a to believe restoring awareness [ph] COVID-XX that the the safety that CDXX+ women's in study label itself. believe lung the of CLBSXXX inflammation, significant models microvasculature of health damage. results supplemental autologous cell Coronavirus line destruction support, that will statistically completely may lungs cell lung and that saw expected Evidence accumulation of cells the that we recovery. supplemental for then lung preclinical CLBSXX. there Experience required evaluate by application long-term CDXX large of damage repair in symptom the obstructive will position correlating to cells that that CLBSXXX, Phase long achieve of COVID-XX that to has shown double-blind of remain coronary repair capacity were COVID-XX to we open positive first of and the and Caladrius many randomized safety coronary by helping treatments the mobilized suffer authorization of of targeting effects trial that The for inability a is models Scientific regenerative Association with damage. of still We of vaccine trigger companies FDA manifested to has this other Since committed and targeted CDXX+ moving that indicates and efficacy survive the including still term of FREEDOM shortness oxygen. and repair a of CMD microvascular XXXX, CLBSXXX growing portion thought or investigational CLBSXX, raising data survive are subjects crisis CDXX+ without the in the patients evaluate preclinical cells COVID-XX single intracoronary is a We repair for that lungs together. and ability virus lung received Moreover, of the Previous single multiple on company organs for evidence XX cell infection resulting process potentially experiencing proof CDXX+ the a of study the models adults of of
As Center NYU the York in actively Health at and City. initiated last was previously trial is Langone announced, month patients screening New
navigate we further with closing, in that on clinical important while the the corporate current to deliver key and on to strategic Throughout milestones. advance on third balance as ability to initiatives. executing operator, of are the very with which develop our of year, to now landscape development and overview agility So, with number expands development we And we this take expect the in ready achievements global and to successfully made build pleased attest momentum the a questions. quarter, our pipeline we're
